X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    FDA Accepts BLA for Recommended

    FDA Accepts BLA for Recommended Biosimilar to Simponi

    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Quanticate Expands Leadership Team with new EVP of Business Development

Content Team by Content Team
18th September 2021
in News
Quanticate appoints new Head of Machine Learning and Digital Transformation

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Quanticate, a leading global data-focused Clinical Research Organization (CRO), has named Nick Darbey as the company’s Executive Vice President of Business Development.

Drawing on Darbey’s proven track record of growing CROs, Quanticate will leverage his business development leadership to support the growth of the business as he joins the company’s executive team.

Reporting to Quanticate’s Chairman and Chief Executive Officer David Underwood, Darbey will work across Quanticate’s global office network (UK, North America, India, South Africa, and Poland), supporting the development and delivery of services that meet evolving client and patient needs.

“Nick is an executive leader with a recognised history of performance, growing businesses at double digit annual figures over multiple years,” said Underwood. “He is a strategic leader with deep knowledge in combining proposals, contracts, business development and marketing expertise with financial and analytical skills.”

Quanticate is one of the world’s largest data-focused CROs and widely known as clinical data experts with an exemplary track record in supporting customers with the most complex study designs and required analysis.

Darbey will further focus Quanticate in its ability to serve drug developers with highly complex clinical data solutions, leveraging the company’s expertise and advanced knowledge of clinical data solutions across biostatistics, statistical programming and clinical data management.

“Quanticate has a fantastic reputation and a long history in supporting pharma and biotech companies over the past three decades as leading data experts in the industry,” said Darbey.

“I’m delighted to be stepping into the role of EVP Business Development and leading the commercial team at Quanticate to build on the great success that has already been achieved. With a focus on the high-quality service and data expertise our customers expect, I am looking forward to driving our business growth and working with all our existing and new customers as we support their needs and complex trials”.

About Quanticate

Quanticate is one of the world’s largest global data-focused clinical research organizations (CROs) with a primary focus on data collection and validation, statistical analysis, and clinical trial reporting. As an expert in clinical data, with a long history spanning across 3 decades, Quanticate can rapidly provide high-quality teams that offer flexible solutions for clinical data management, biostatistics, statistical programming, pharmacokinetic/pharmacodynamic (PK/PD) analysis, medical writing, and statistical consultancy. Quanticate meets the needs of drug and device development companies by offering customer focused resource solutions from fixed cost or functional service provider (FSP) models through to consultancy. Quanticate has become the trusted supplier of choice for many companies from niche biotechnology and device companies to top tier pharmaceutical giants.

Previous Post

BMG Pharma and HTL sign a development agreement to manufacture BMG's new biopolymer based on the Hyaluromimethic Technology

Next Post

Celltrion's regdanvimab becomes the first authorized COVID-19 treatment approved from the Korean MFDS

Related Posts

FDA Accepts BLA for Recommended
FDA Approvals

FDA Accepts BLA for Recommended Biosimilar to Simponi

22nd July 2025
Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
Next Post
Celltrion's regdanvimab becomes the first authorized COVID-19 treatment approved from the Korean MFDS

Celltrion's regdanvimab becomes the first authorized COVID-19 treatment approved from the Korean MFDS

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In